- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05083884
A Survey About Hot Flashes in Women Going Through the Menopause
Prospective Survey of Women With Vasomotor Symptoms Associated With Menopause in Nordic Europe, Canada, Brazil and Mexico - WARM Study
This study is an online survey of women in and around menopause with moderate to severe hot flashes. Menopause, a normal part of life, is a time after a woman's last period. Hot flashes often occur during menopause. They can disrupt a woman's daily life.
This study is about collecting information only. There will be no treatment in this study.
This study will provide information about how many women have moderate to severe hot flashes in menopause. It will also provide details on women's experiences with hot flashes.
Women from Brazil, Canada, Nordic Europe, and Mexico will take part in this study. The women in this study will already be taking part in consumer panels. Women will be contacted based on their age. They will be asked if they would like to take part in this study.
Firstly, the women will answer questions about whether they are in menopause or are getting close to menopause. They will also be asked how severe their hot flashes are.
From their answers, some women will be asked to complete an online survey. These will be women who are in menopause and have moderate to severe hot flashes. They will provide more details about how hot flashes have impacted their lives. Also, they will answer questions on how hot flashes affect their quality of life. Finally, they will answer questions about their experiences when they visited their doctor about their hot flashes.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, N1 8JY
- IQVIA
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria (primary outcome measure):
- Post-menopausal women
Inclusion Criteria (secondary outcome measure):
- Women currently experiencing, or have experienced in the last month, moderate to severe VMS symptoms (i.e. minimum of 1 moderate to severe hot flushes per day over the last month)
- Peri-menopausal and post-menopausal women
Exclusion Criteria (primary outcome measure):
- Women with current breast cancer treatment
- Women treated with anti-estrogens, aromatase inhibitors or Gonadotropin-releasing hormone (GnRH) agonists/antagonists for cancer or any other medical condition.
Additional exclusion criterion for secondary outcome measures will be:
- Mild VMS symptoms only
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Group 1: Peri-menopausal woman
Grouping is based on Peri-menopausal woman
|
This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
|
Group 2: Post- menopausal woman
Grouping is based on Post-menopausal woman
|
This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
|
Group 3: Peri-menopausal woman: moderate-to-severe MR-VMS
Grouping is based on Peri-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
|
This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
|
Group 4: Post-menopausal woman: moderate-to-severe MR-VMS
Grouping is based on Post-menopausal woman with moderate-to-severe vasomotor symptoms (MR-VMS)
|
This is a cross-sectional non-product related survey including peri- and post-menopausal women with moderate to severe VMS associated with menopause.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of moderate to severe vasomotor symptoms (VMS) in post-menopausal women
Time Frame: 1 day (once through survey)
|
Prevalence of moderate to severe VMS in post-menopausal women.
Post-menopause is defined as at least 12 consecutive months without a period.
Moderate VMS associated with menopause symptoms is defined as sensations of heat with sweating but being able to continue activities.
Severe VMS associated with menopause is defined as feelings of intense heat with sweating causing cessation of activities.
The recall period is 1 month prior to survey.
|
1 day (once through survey)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Health Related Quality of Life (HRQoL) measured by the Menopause Specific QoL Questionnaire (MENQoL)
Time Frame: 1 day (once through survey)
|
MENQoL measures the overall score and four domain-specific scores assessing wellbeing (vasomotor; psychosocial; physical; sexual).
Scores range from 1 to 8 with a higher score indicating worsening/increasing bothersomeness by the symptom experience.
The MENQoL recall period is 7 days prior to survey.
|
1 day (once through survey)
|
Health Related Quality of Life (HRQoL) measured by Work Productivity and Activity Impairment-VMS (WPAI-VMS) Questionnaire
Time Frame: 1 day (once through survey)
|
The WPAI-VMS questionnaire measures four domain specific scores assessing work productivity and activity impairment over the previous week (absenteeism; presenteeism; mean work productivity; activity impairment).
Scores range from 0 to 100%.
The four scores were expressed as impairment percentages with a higher score indicating less productivity and greater activity impairment.
The WPAI recall period is 7 days prior to survey.
|
1 day (once through survey)
|
Health Related Quality of Life (HRQoL) measured by Patient-Reported Outcomes Measurement Information System - Sleep Disturbance (PROMIS)
Time Frame: 1 day (once through survey)
|
The PROMIS Sleep Disturbance instrument assesses self-reported perceptions of sleep quality, sleep depth, and restoration associated with sleep. This includes perceived difficulties and concerns with getting to sleep or staying asleep, as well as perceptions of the adequacy of and satisfaction with sleep. Each item on the measure is rated on a 5-point scale with a range in score from 8 to 40 with higher scores indicating greater severity of sleep disturbance. The PROMIS recall period is 7 days prior to survey. (Only implemented in Canada, Brazil and Denmark). |
1 day (once through survey)
|
Proportion of Participants with VMS seeking healthcare professionals' (HCP) advice
Time Frame: 1 day (once through survey)
|
The type of specialists reported by peri- and post-menopausal women will be assessed.
|
1 day (once through survey)
|
Proportion of Participants with VMS taking over the counter treatment for moderate to severe VMS symptoms
Time Frame: 1 day (once through survey)
|
The types of over the counter treatment taken by peri- and post-menopausal women for MR symptoms will be assessed.
|
1 day (once through survey)
|
Proportion of Participants incurring average out-of-pocket expenses incurred in treatment of menopause
Time Frame: 1 day (once through survey)
|
Average out-of-pocket expenses incurred in the treatment of menopause reported by medications bought will be assessed.
|
1 day (once through survey)
|
Percentage of peri-and post-menopausal women who seek help from HCPs for their menopause related symptoms (MR-VMS)
Time Frame: 1 day (once through survey)
|
Percentage of peri- and post-menopausal women who seek help from Health Care Professionals (HCPs) for their MR-VMS.
Help from an HCP can be in the form of advice or receipt of pharmaceutical treatment.
|
1 day (once through survey)
|
Health Related Quality of Life (HRQoL) measured by participants' attitudes to their VMS
Time Frame: 1 day (once through survey)
|
Participants' attitudes towards their VMS will be evaluated using the following: agreement or disagreement to statements on menopause itself, available treatments, and willingness/aversion to hormone replacement therapy (HRT).
|
1 day (once through survey)
|
Treatment patterns of peri- and post-menopausal women assessed by type of treatment
Time Frame: 1 day (once through survey)
|
The number of peri- and post-menopausal women treated with hormonal treatment, non-hormonal treatment, or other approaches will be summarized.
|
1 day (once through survey)
|
Treatment patterns of peri- and post-menopausal assessed by length of time on hormonal treatment
Time Frame: 1 day (once through survey)
|
The length of time on hormonal treatment in peri- and post-menopausal women will be summarized.
|
1 day (once through survey)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Medical Affairs Europe
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 2693-MA-3235
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vasomotor Symptoms
-
Hansoh BioMedical R&D CompanyRecruiting
-
BayerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVasomotor SymptomsMexico
-
Mitsubishi Tanabe Pharma America Inc.CompletedVasomotor Symptoms (VMS)United States
-
Duramed ResearchCompletedNocturnal Vasomotor SymptomsUnited States
-
Mitsubishi Tanabe Pharma CorporationCompleted
-
BayerCompletedVasomotor SymptomsKorea, Republic of
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; Spaulding Rehabilitation HospitalWithdrawnVasomotor Symptoms | Cardiovascular HealthUnited States
-
PfizerCompletedVasomotor SymptomsCanada, United States
Clinical Trials on No Intervention
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Case Western Reserve UniversityAmerican University; Purdue UniversityRecruiting
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted
-
Hôpital Necker-Enfants MaladesUnknown